TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是了解在哮喘控制良好的儿童中停止每天使用吸入性皮质类固醇(ICS)治疗是否安全。这项研究的另一个目的是看看在需要抢救药物的时候同时使用沙丁胺醇和吸入皮质类固醇是否比单独使用沙丁胺醇能更好地预防哮喘发作。 这项研究的第三个目的是了解年龄、性别、哮喘和过敏家族史、过敏程度和遗传等个人特征可能与每种药物的良好反应或不良反应有关。你的血液样本将接受与呼吸系统、过敏和哮喘药物相关的化学和细胞特性测试。此外，还将对您的血液进行基因分析。如果你的亲生父母同意参与这项研究的遗传学部分，他们将被要求签署一份单独的同意书。这些发现可能有助于研究人员了解某些基因与儿童对研究药物的反应之间可能存在的联系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to see if it is safe to stop using daily inhaled corticosteroid (ICS) therapy in children who are under good asthma control using inhaled corticosteroids. Another purpose of the study is to see if using both albuterol and inhaled corticosteroids whenever rescue medicine is needed will provide better protection against asthma attacks than using albuterol alone. A third purpose of the research study is to see what individual characteristics like age, gender, family history of asthma and allergies, the degree of allergy, and genetics, may be linked with either a good or poor response to each of the medications. Your blood sample will be tested for chemical and cellular properties related to your respiratory system, allergies, and asthma medications. In addition, a genetic analysis will be performed on your blood. Your biological parent will be asked to sign a separate consent if they agree to participate in the genetics portion of this study. These findings may help investigators to understand possible links between certain genes and how children respond to the study medications.